{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T18:40:46Z","timestamp":1771526446817,"version":"3.50.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,1,1]],"date-time":"2004-01-01T00:00:00Z","timestamp":1072915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T00:00:00Z","timestamp":1417478400000},"content-version":"vor","delay-in-days":3988,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2004,1]]},"DOI":"10.1111\/j.1469-0691.2004.00747.x","type":"journal-article","created":{"date-parts":[[2004,1,6]],"date-time":"2004-01-06T05:18:19Z","timestamp":1073366299000},"page":"62-69","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["The use and therapeutic drug monitoring of teicoplanin in the UK"],"prefix":"10.1016","volume":"10","author":[{"given":"E.S.R.","family":"Darley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.P.","family":"MacGowan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2004.00747.x_bib1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1128\/AAC.33.6.871","article-title":"Evaluation of teicoplanin for treatment of endocarditis caused by Gram-positive cocci in 20 patients","volume":"33","author":"Leport","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0163-4453(98)80166-7","article-title":"Infective endocarditis and glycopeptides","volume":"37","author":"Pittet","year":"1998","journal-title":"J Infect"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib3","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1128\/AAC.34.12.2392","article-title":"Treatment of bone, joint and vascular-access-associated Gram-positive bacterial infections with teicoplanin","volume":"34","author":"Greenberg","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/jac\/45.6.835","article-title":"Teicoplanin therapy for S. aureus septicaemia: relationship between pre-dose serum concentrations and outcome","volume":"45","author":"Harding","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF02355116","article-title":"Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome","volume":"2","author":"MacGowan","year":"1996","journal-title":"J Infect Chemother"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2004.00747.x_bib6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/0924-8579(94)90049-3","article-title":"A critical review of the dosage of teicoplanin in Europe and the USA","volume":"4","author":"Wilson","year":"1994","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib7","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/jac\/37.3.545","article-title":"Pharmacokinetics of a single dose of teicoplanin in burn patients","volume":"37","author":"Steer","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib8","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1128\/AAC.35.6.1089","article-title":"Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin","volume":"35","author":"Bailey","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"issue":"suppl 1","key":"10.1111\/j.1469-0691.2004.00747.x_bib9","first-page":"205","article-title":"The use and therapeutic drug monitoring (TDM) of teicoplanin in the UK","volume":"6","author":"Darley","year":"2000","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib10","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1128\/AAC.35.1.79","article-title":"Failure of treatment with teicoplanin at 6 milligrams\/kilogram\/day in patients with S. aureus intravascular infection","volume":"35","author":"Gilbert","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib11","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/1120009X.1991.11739112","article-title":"An open study of teicoplanin in the treatment of Gram-positive infections","volume":"3","author":"Nathwani","year":"1991","journal-title":"J Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib12","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jac\/31.5.755","article-title":"The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria","volume":"31","author":"Presterl","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib13","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/jac\/37.3.623","article-title":"Impact of glycopeptide therapy after hospital discharge on inpatient costs: a comparison of teicoplanin and vancomycin","volume":"37","author":"Davey","year":"1996","journal-title":"J Antimicrob Chemother"},{"issue":"suppl","key":"10.1111\/j.1469-0691.2004.00747.x_bib14","first-page":"23","article-title":"Teicoplanin-home therapy for prosthetic joint infections","volume":"567","author":"Davey","year":"1992","journal-title":"Eur J Surg"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib15","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF01690746","article-title":"Experience with outpatient intravenous teicoplanin therapy for chronic osteomyelitis","volume":"14","author":"Graninger","year":"1995","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib16","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1365-2257.1995.tb00321.x","article-title":"Teicoplanin and oral ciprofloxacin as outpatient treatment of infective episodes in patients with indwelling central venous catheters and haematological malignancy","volume":"17","author":"Ketley","year":"1995","journal-title":"Clin Lab Haematol"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0924-8579(97)00054-X","article-title":"Retrospective study of teicoplanin as home continuation of hospital-initiated therapy","volume":"9","author":"South","year":"1998","journal-title":"Int J Antimicrob Agents"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib18","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/BF01713981","article-title":"Teicoplanin: a well tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients","volume":"20","author":"Charbonneau","year":"1994","journal-title":"Intensive Care Med"},{"issue":"suppl B","key":"10.1111\/j.1469-0691.2004.00747.x_bib19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/jac\/27.suppl_B.69","article-title":"A review of the safety profile of teicoplanin","volume":"27","author":"Davey","year":"1991","journal-title":"J Antimicrob Chemother"},{"issue":"suppl A","key":"10.1111\/j.1469-0691.2004.00747.x_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/jac\/21.suppl_A.61","article-title":"A multicentre open clinical trial of teicoplanin in infections caused by Gram-positive bacteria","volume":"21","author":"Lewis","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib21","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/clinids\/18.4.533","article-title":"Serum vancomycin concentrations: reappraisal of their clinical value","volume":"18","author":"Cant\u00fa","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1093\/jac\/37.2.209","article-title":"The comparative efficacy and safety of teicoplanin and vancomycin","volume":"37","author":"Wood","year":"1996","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib23","first-page":"701","article-title":"Breakpoints in in-vitro antibiotic sensitivity testing. Report by a Working Party of the British Society for Antimicrobial Chemotherapy","volume":"21","author":"British Society for Antimicrobial Chemotherapy","year":"1988","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib24","first-page":"225","article-title":"Comparison of the in vitro antibacterial activity of teicoplanin and vancomycin against Gram-positive cocci","volume":"13","author":"Ravizzola","year":"1987","journal-title":"Drugs Exp Clin Res"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib25","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1128\/AAC.35.4.696","article-title":"Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis","volume":"35","author":"Ryback","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib26","doi-asserted-by":"crossref","first-page":"292","DOI":"10.2165\/00003088-198712040-00003","article-title":"Teicoplanin pharmacokinetics in patients with chronic renal failure","volume":"12","author":"Bonati","year":"1987","journal-title":"Clin Pharmacol"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0924-8579(99)00006-0","article-title":"The role of glycopeptide antibiotics in the treatment of infective endocarditis","volume":"12","author":"Gr\u00fcneberg","year":"1999","journal-title":"Int J Antimicrob Agents"},{"issue":"suppl","key":"10.1111\/j.1469-0691.2004.00747.x_bib28","first-page":"9","article-title":"Teicoplanin in the treatment of bone and joint infections","volume":"567","author":"Le Frock","year":"1992","journal-title":"Eur J Surg"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib29","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/BF02276052","article-title":"Use of teicoplanin in community medicine","volume":"13","author":"Wilson","year":"1994","journal-title":"Eur J Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib30","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/jac\/30.3.399-a","article-title":"Serum monitoring of teicoplanin","volume":"30","author":"MacGowan","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/jac\/32.6.792","article-title":"Dosage recommendations for teicoplanin","volume":"32","author":"Wilson","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib32","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/hrt.79.2.207","article-title":"Antibiotic treatment of streptococcal, enterococcal and staphylococcal endocarditis","volume":"79","author":"Working Party of the British Society for Antimicrobial Chemotherapy","year":"1998","journal-title":"Heart"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib33","series-title":"Mandell, Douglas and Bennett's principles and practice of infectious diseases","first-page":"1767","article-title":"S. aureus (including toxic shock syndrome)","author":"Waldvogel","year":"1995"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib34","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1128\/AAC.33.1.82","article-title":"Pharmacokinetics of single- and multiple-dose teicoplanin in healthy volunteers","volume":"33","author":"Carver","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2004.00747.x_bib35","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1128\/AAC.34.11.2114","article-title":"Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses","volume":"34","author":"Outman","year":"1990","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14636958?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14636958?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:18:04Z","timestamp":1761117484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14636958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,1]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,1]]}},"alternative-id":["S1198743X14636958"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.00747.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2004,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The use and therapeutic drug monitoring of teicoplanin in the UK","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1469-0691.2004.00747.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}